News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Opinion Editor's Corner ESC 2023 What’s Going to Be Hot at ESC 2023? Shelley Wood August 15, 2023
News Conference News ESC 2022 DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum Todd Neale August 27, 2022
News Conference News ESC 2022 Old Drug Acetazolamide Offers New Tricks in Acute HF: ADVOR L.A. McKeown August 27, 2022
News Conference News ESC 2022 No Hints of Cognitive Defects With ARNIs in HFpEF: PERSPECTIVE Shelley Wood August 26, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2021 New ESC HF Guidelines Showcase SGLT2 Inhibitors, Tafamidis, Vericiguat, and COAPT Shelley Wood August 28, 2021
News Conference News ESC 2021 EMPEROR-Preserved: Empagliflozin Improves Outcomes in HFpEF Todd Neale August 27, 2021
News Opinion Editor's Corner ESC 2021 ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress Shelley Wood August 19, 2021
News Conference News ESC 2020 PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF Todd Neale August 30, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Conference News ESC 2019 PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen Todd Neale September 01, 2019
News Conference News ESC 2019 ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More Shelley Wood August 22, 2019